8-K: Mineralys Files Lorundrostat NDA, Reports Positive Trial Data

Mineralys Therapeutics announced the submission of a New Drug Application for lorundrostat to the FDA and confirmed it is on track to report Phase 2 Explore-OSA trial results in Q1 2026.

Summary

• Mineralys Therapeutics filed a New Drug Application (NDA) for lorundrostat with the U.S. Food and Drug Administration (FDA) in late 2025.
• The company remains on track to report topline results from its Phase 2 Explore-OSA trial, which evaluates lorundrostat for moderate to severe obstructive sleep apnea and hypertension, in the first quarter of 2026.
• Lorundrostat demonstrated a best-in-class safety and 24-hour blood pressure control profile across diverse patient populations in three positive clinical trials completed in 2025.
• The ongoing Transform-HTN Open-Label Extension Trial continues to gather additional long-term safety and efficacy data for lorundrostat.
• Positive data from the Phase 2 Explore-CKD trial showed lorundrostat met its primary endpoint on systolic blood pressure reduction and demonstrated meaningful proteinuria reduction in participants with hypertension, reduced kidney function, and albuminuria.
• The pivotal Launch-HTN Phase 3 trial met its primary endpoint in evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) as add-on therapy.
• The pivotal Advance-HTN trial also met its primary endpoints in evaluating the efficacy and safety of lorundrostat for the treatment of confirmed uHTN or rHTN on top of optimized, standardized AHA guideline background medications.
• Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor with 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours, and demonstrated a 40-70% reduction in plasma aldosterone concentration in hypertensive participants.

Sentiment

Score: 8

Explanation: The filing reports significant positive clinical and regulatory milestones, including the NDA submission for lorundrostat and successful outcomes from multiple pivotal trials, indicating strong progress and potential for market entry. The 'best-in-class profile' claim further boosts sentiment.

Positives

• NDA for lorundrostat filed with the FDA in late 2025, marking a significant regulatory milestone.
• Remains on track to report topline results from the Phase 2 Explore-OSA trial in Q1 2026.
• Lorundrostat demonstrated a "best-in-class profile" with clinically meaningful blood pressure reduction, 24-hour control, benefit across difficult-to-treat patients, and a favorable safety and tolerability profile.
• Three positive clinical trials completed in 2025 supported the NDA submission.
• Phase 2 Explore-CKD trial met its primary endpoint on systolic blood pressure reduction and showed meaningful proteinuria reduction.
• Pivotal Launch-HTN Phase 3 trial met its primary endpoint for efficacy and safety in uncontrolled or resistant hypertension.
• Pivotal Advance-HTN trial met its primary endpoints for efficacy and safety in confirmed uncontrolled or resistant hypertension.
• Lorundrostat was well tolerated in both pivotal trials with a favorable safety profile.

Risks

• Topline results are based on preliminary analysis and such data may change following a more comprehensive review, potentially not accurately reflecting the complete results of a clinical trial.
• Future performance is entirely dependent on the success of lorundrostat.
• Potential delays in the commencement, enrollment, and completion of clinical trials and nonclinical studies.
• Later developments with the FDA may be inconsistent with prior feedback, including whether the proposed pivotal program will support registration of lorundrostat.
• Any delays in the FDA's review of the NDA submission, including as a result of a government shutdown or reductions in agency funding or personnel.
• Results of clinical trials, including the Advance-HTN and Launch-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for an NDA submission or regulatory approval of lorundrostat.
• Dependence on third parties in connection with manufacturing, research, and clinical and nonclinical testing.
• Unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval, and/or commercialization.
• Unfavorable results from clinical trials and nonclinical studies.
• Results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results.
• Macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs, and the potential for a local and/or global economic recession.
• Ability to maintain undisrupted business operations due to any pandemic or future public health concerns.
• Regulatory developments in the United States and foreign countries.
• Reliance on an exclusive license with Mitsubishi Tanabe Pharma to provide intellectual property rights to develop and commercialize lorundrostat.
• Other risks described in SEC filings, including under the heading Risk Factors in the annual report on Form 10-K, and any subsequent filings with the SEC.

Future Outlook

The company expects the Explore-OSA data in Q1 2026 to further support its strategy to extend lorundrostat's profile in treating patients with hypertension and comorbid conditions. They also anticipate the potential therapeutic benefits of lorundrostat and the possibility that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients. The company believes the Advance-HTN and Launch-HTN trials may serve as pivotal trials for NDA submission to the FDA.

Management Comments

• "As we reflect on the data generated with lorundrostat to date, we are more confident than ever of the drug candidates best-in-class profile, based on the clinically meaningful blood pressure reduction, the demonstrated 24-hour control, its benefit across the spectrum of difficult-to-treat patients, and its safety and tolerability profile." Jon Congleton, Chief Executive Officer of Mineralys Therapeutics.
• "We look forward to reporting the Explore-OSA data in the first quarter of 2026, which we expect will further support our strategy to extend lorundrostat's profile in treating patients with hypertension and comorbid conditions." Jon Congleton, Chief Executive Officer of Mineralys Therapeutics.

Industry Context

Mineralys Therapeutics is developing lorundrostat, an aldosterone synthase inhibitor, for hypertension and related comorbidities like chronic kidney disease (CKD) and obstructive sleep apnea (OSA). This aligns with a broader industry trend focusing on targeted therapies for complex cardiovascular and renal diseases, particularly for difficult-to-treat patient populations where existing therapies may be insufficient. The company's claim of a "best-in-class profile" suggests an aim to differentiate in a competitive market for hypertension treatments by offering superior efficacy and safety.

Comparison to Industry Standards

• Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, indicating a highly targeted mechanism of action.
• Demonstrated a 40-70% reduction in plasma aldosterone concentration in hypertensive participants, providing a quantitative measure of its pharmacological effect.
• The company claims a "best-in-class profile" based on clinically meaningful blood pressure reduction, 24-hour control, and safety/tolerability, implying a favorable comparison to other treatments for uncontrolled/resistant hypertension.
• The pivotal Advance-HTN trial reinforced lorundrostat's favorable benefit-risk profile in a high-risk population typically treated by specialists, suggesting it meets or exceeds the needs for this specific patient group.

Stakeholder Impact

• Shareholders: Positive impact due to significant progress in drug development, NDA submission, and successful trial results, potentially leading to increased share value.
• Patients (Hypertension, CKD, OSA): Potential for a new, effective treatment option with a favorable safety profile, especially for difficult-to-treat cases.
• FDA: Will be reviewing the NDA, impacting regulatory timelines and potential market approval.
• Employees: Positive outlook due to company progress and potential for future commercialization.

Next Steps

• FDA review of the lorundrostat NDA.
• Reporting of topline results from the Phase 2 Explore-OSA trial in Q1 2026.
• Continued gathering of long-term safety and efficacy data from the Transform-HTN Open-Label Extension Trial.
• Participation in the LifeSci Partners Corporate Access event on January 12-14, 2026.

Key Dates

Recommendation

The filing details several highly positive developments, including the submission of a New Drug Application (NDA) for lorundrostat to the FDA, which is a critical step towards commercialization. The drug has demonstrated a "best-in-class profile" with clinically meaningful blood pressure reduction, 24-hour control, and a favorable safety and tolerability profile across multiple successful Phase 2 and Phase 3 trials (Explore-CKD, Launch-HTN, Advance-HTN). These results validate lorundrostat's efficacy in difficult-to-treat hypertension and related comorbidities. The upcoming Phase 2 Explore-OSA trial results in Q1 2026 offer further potential upside. The company's strong clinical data and regulatory progress significantly de-risk the investment, making it a compelling "strong buy" for investors seeking exposure to innovative cardiovascular and renal therapies.

Keywords

Mineralys Therapeutics, MLYS, lorundrostat, hypertension, obstructive sleep apnea, OSA, chronic kidney disease, CKD, aldosterone synthase inhibitor, NDA, FDA, clinical trials, Phase 2, Phase 3, drug development, biopharmaceutical, cardiovascular, renal disease